🚀
Enjoy a 7-Day Free Trial Thru May 03, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Oramed Pharmaceuticals Inc (NAS:ORMP)
News
Oramed Pharmaceuticals Inc
NAS
:ORMP (USA) Â
$ 2.30
-0.07 (-2.95%)
10:08 PM EST
P/E:
16.43
P/B:
0.57
Market Cap:
$ 93.19M
Enterprise V:
$ -14.39M
Volume:
107.26K
Avg Vol (2M):
135.97K
Warning! GuruFocus detected 6 Severe warning signs with ORMP.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
107.26K
Market Cap $:
93.19M
PE Ratio:
16.43
Avg Vol (2M):
135.97K
Enterprise Value $:
-14.39M
PB Ratio:
0.57
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Oramed Pharmaceuticals Inc (NAS:ORMP) Stock News, Headlines & Updates
Oramed Pharmaceuticals Inc Stock News from GuruFocus
Total 90
1
2
3
Feb 20, 2024
Oramed Letter to Shareholders
PRNewswire
•
8:00am
Feb 08, 2024
Oramed Pharmaceuticals Inc at Issuer Direct Planet MicroCap Showcase (Virtual) Transcript
GuruFocus Research
•
8:14am
Oramed Pharmaceuticals Inc NASH Data and KOL Webinar Transcript
GuruFocus Research
•
8:14am
Oramed Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
GuruFocus Research
•
8:14am
Oramed Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript
GuruFocus Research
•
8:14am
Genomma Lab Internacional SAB de CV & Oramed Pharmaceuticals Inc & Oravax Medical Inc Joint Venture Press Conference Transcript
GuruFocus Research
•
8:14am
Oramed Pharmaceuticals Inc The Journey of Oral Insulin: The Oramed Story Transcript
GuruFocus Research
•
8:14am
Sep 22, 2023
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
PRNewswire
•
11:00am
Sep 21, 2023
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
PRNewswire
•
6:00pm
Aug 02, 2023
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
PRNewswire
•
7:00am
Feb 02, 2022
Thinking about buying stock in Oramed Pharmaceuticals, Allegheny Technologies, Evercore, Vertex Energy, or AST SpaceMobile?
PRNewswire
•
9:01am
Jul 21, 2021
Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial
PRNewswire
•
8:02am
May 25, 2021
Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine
PRNewswire
•
8:03am
Apr 21, 2021
Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners' Grand Rounds: A Webinar in Biotech and Specialty Pharma
PRNewswire
•
7:01am
Mar 04, 2021
Oramed to Present at H.C. Wainwright Global Life Sciences Conference 2021
PRNewswire
•
11:04am
Jan 27, 2021
Oramed Issues Letter to Shareholders
PRNewswire
•
11:03am
Jan 21, 2021
Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
PRNewswire
•
11:03am
Jan 07, 2021
Oramed to Present at H.C. Wainwright BioConnect 2021 Conference
PRNewswire
•
11:02am
Dec 23, 2020
Oramed Reports Positive First in Human Data from Oral Leptin Study
PRNewswire
•
11:01am
Dec 02, 2020
Oramed Initiates Phase 2 NASH Trial of Oral Insulin
PRNewswire
•
11:03am
Nov 24, 2020
Oramed Initiates Phase 3 Trial of Oral Insulin
PRNewswire
•
11:03am
Nov 12, 2020
Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020
PRNewswire
•
11:01am
Nov 10, 2020
Oramed to Present at H.C. Wainwright 6th Annual Israel Conference
PRNewswire
•
11:02am
Oct 28, 2020
Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference
PRNewswire
•
11:03am
Oct 27, 2020
Oramed CEO Nadav Kidron & Premas Biotech to Host Webinar "The Journey of Oral Insulin: Oramed Story" on Wednesday October 28, 2020
PRNewswire
•
11:04am
Oct 16, 2020
Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA
PRNewswire
•
11:02am
Sep 21, 2020
Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting
PRNewswire
•
11:02am
Sep 15, 2020
Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients
PRNewswire
•
11:04am
Sep 03, 2020
Oramed to Present at H.C. Wainwright Global Investment Conference
PRNewswire
•
11:03am
Jul 15, 2020
Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
PRNewswire
•
11:01am
Jul 08, 2020
Insulin in Pill Form Would Be a Bonanza for Oramed
Barry Cohen
•
4:09pm
Jun 15, 2020
Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin
PRNewswire
•
11:02am
May 05, 2020
Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June
PRNewswire
•
7:03am
Apr 07, 2020
Oramed Patent in Canada Allowed for Oral Delivery of Proteins
PRNewswire
•
7:00am
Apr 01, 2020
Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19
PRNewswire
•
11:02am
Mar 19, 2020
Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA
PRNewswire
•
11:02am
Feb 27, 2020
Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million
PRNewswire
•
11:05am
Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock
PRNewswire
•
7:02pm
Feb 26, 2020
Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
PRNewswire
•
7:01am
Feb 04, 2020
Oramed to Present at BIO CEO & Investor Conference
PRNewswire
•
11:02am
Total 90
1
2
3
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news